141 related articles for article (PubMed ID: 9215398)
1. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
Culig Z; Hobisch A; Hittmair A; Cronauer MV; Radmayr C; Zhang J; Bartsch G; Klocker H
Prostate; 1997 Jul; 32(2):106-14. PubMed ID: 9215398
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
4. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Berrevoets CA; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
[TBL] [Abstract][Full Text] [Related]
5. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
6. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
7. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
[TBL] [Abstract][Full Text] [Related]
8. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.
Le HT; Schaldach CM; Firestone GL; Bjeldanes LF
J Biol Chem; 2003 Jun; 278(23):21136-45. PubMed ID: 12665522
[TBL] [Abstract][Full Text] [Related]
9. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
Desiniotis A; Schäfer G; Klocker H; Eder IE
Int J Cancer; 2010 Feb; 126(3):775-89. PubMed ID: 19653278
[TBL] [Abstract][Full Text] [Related]
11. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.
Heer R; Robson CN; Shenton BK; Leung HY
J Cell Physiol; 2007 Sep; 212(3):572-8. PubMed ID: 17541959
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation.
Ikonen T; Palvimo JJ; Kallio PJ; Reinikainen P; Jänne OA
Endocrinology; 1994 Oct; 135(4):1359-66. PubMed ID: 7925097
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
14. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
[TBL] [Abstract][Full Text] [Related]
15. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
17. Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer.
Shain SA
Mol Urol; 2001; 5(3):121-30. PubMed ID: 11690559
[TBL] [Abstract][Full Text] [Related]
18. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types.
Blok LJ; Themmen AP; Peters AH; Trapman J; Baarends WM; Hoogerbrugge JW; Grootegoed JA
Mol Cell Endocrinol; 1992 Oct; 88(1-3):153-64. PubMed ID: 1334008
[TBL] [Abstract][Full Text] [Related]
20. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Simard J; Singh SM; Labrie F
Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]